Urinary incontinence is a growing health problem with increasing social and economic significance--the direct and indirect costs of treating it total almost $20 billion in the US alone. Device companies are providing a variety of treatment options for patients with UI, including a growing number of increasingly less invasive surgical options.
by Anne Staylor and Mary Thompson
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Back-to-back meetings at LSX? No time to attend the innovator showcase? Here is what you might have missed from medtech innovators at the LSX World Congress Europe on 29 April.
HistoSonics, which developed a noninvasive technology to destroy tumor cells, reports 90% local tumor control at 12-month follow-up in the #HOPE4Liver Trial. The Edison System, cleared by the US FDA in late 2023, is also being evaluated for kidney and pancreatic tumors. CEO Mike Blue said the medtech is financially secure but watching public markets as it considers an IPO.
Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.